Pops: merger will "transform" Alkermes-EDT into "fully integrated company"
This article was originally published in Scrip
Executive Summary
The merger of Alkermes with Elan Drug Technologies (EDT) – subject to a shareholder vote in September 2011 - will result in the perception of Alkermes as a drug delivery company to change completely, Alkermes' CEO Richard Pops told Scrip. "The transaction will have the effect of significantly accelerating the business plan we have been looking at for the past few years," he explained. "We have been using our drug delivery partnerships as a stepping stone on the way to becoming a fully integrated company with an innovative pipeline of products." In addition, combining the two companies will be "financially transformative… When we put these two together, there will be very few comparable companies".